Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Felipe Galvan

Physician Assistant, Medical San Antonio, TX Physician Assistant

NPI 1841327459 CMS profile 10686659

16110 Via Shavano, San Antonio, TX 78249

Open in the dashboard

General payments

$25,594

1,183 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Felipe Galvan of San Antonio, TX is reported in the CMS Open Payments database as having received $25,594 across 1,183 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,444 297
2024 General $6,142 282
2023 General $4,553 235
2022 General $4,834 202
2021 General $3,620 167

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Felipe Galvan
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Felipe Galvan were reported at $6,444. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Felipe Galvan Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $3,620 $156 $41–$563 $132
2022 $4,834 $185 $55–$649 $149
2023 $4,553 $199 $58–$717 $160
2024 $6,142 $206 $62–$740 $164
2025 $6,444 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,546 195 payments
  2. Janssen Biotech, Inc. $2,717 172 payments
  3. Incyte Corporation $2,011 89 payments
  4. Galderma Laboratories, L.P. $1,962 85 payments
  5. UCB, Inc. $1,616 61 payments
  6. E.R. Squibb & Sons, L.L.C. $1,420 65 payments
  7. Lilly USA, LLC $1,292 50 payments
  8. Ortho Dermatologics, a division of Bausch Health US, LLC $1,292 51 payments
  9. Regeneron Healthcare Solutions, Inc. $1,014 55 payments
  10. Dermavant Sciences, Inc. $1,005 23 payments
  11. Other $7,720 337 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $24,574 1,170 payments
  2. Education $1,010 12 payments
  3. Travel and Lodging $10 1 payment
Products named General payments · program years 2021–2025
  1. TREMFYA $3,296 170 payments
  2. RINVOQ $2,152 141 payments
  3. OPZELURA $1,779 87 payments
  4. SOTYKTU $1,387 63 payments
  5. DUPIXENT $1,280 54 payments
  6. TALTZ $1,117 45 payments
  7. Bimzelx $1,055 35 payments
  8. VTAMA $1,026 24 payments
  9. JUBLIA $1,008 40 payments
  10. SKYRIZI $853 36 payments
  11. Other $13,544 646 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

599

Median for Physician Assistant: 241

Drug cost

$219,040

Median for Physician Assistant: $4,110

Branded share of claims

8.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Taltz Autoinjector Ixekizumab Brand 11 $69,931
Dupixent Pen Dupilumab Brand 17 $63,241
Dupixent Syringe Dupilumab Brand 13 $49,537
Opzelura Ruxolitinib Phosphate Brand 11 $21,989
Clobetasol Propionate Generic 80 $4,098
Betamethasone Dipropionate Generic 49 $2,461
Doxycycline Hyclate Generic 67 $1,775
Triamcinolone Acetonide Generic 133 $1,442
Ketoconazole Generic 109 $1,292
Tacrolimus Generic 13 $1,282

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$51,591

Of which drugs: $8,498

Medicare patients

270

Average age 73

Services billed

2,155

132 women, 138 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 50%
Diabetes 37%
Chronic kidney disease 27%
Ischemic heart disease 23%
Depression 20%
Atrial fibrillation 15%
Cancer 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 17 24 $7,345

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$775 — —
SOTYKTU
$752 — —
RINVOQ
$577 — —
OPZELURA
$491 11 —
VTAMA
$366 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

1,183 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record